A Placebo and Active-Comparator Controlled Multiple-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of MK-4618 in Patients With Overactive Bladder.
Phase of Trial: Phase I
Latest Information Update: 30 Sep 2016
At a glance
- Drugs Vibegron (Primary) ; Cefalexin; Levofloxacin; Tolterodine
- Indications Overactive bladder
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 03 Feb 2014 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
- 07 May 2013 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 25 Jan 2013 Planned End Date changed from 1 Jun 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.